Abu Dhabi is taking another step towards an AI-driven economy, with healthcare emerging as one of the areas where advanced technology could make a practical difference.

M42, the Abu Dhabi-based healthcare group, plans to adopt Oracle Health Data Intelligence to bring clinical records, genomic information and real-world health data into a more connected system. The aim is to give doctors and researchers a clearer picture of patients’ health while supporting personalised treatment, chronic disease management and wider public health programmes.

Announced on 15 September 2026, the initiative builds on an existing partnership between M42 and Oracle Health. The companies plan to combine Oracle Health Data Intelligence with Oracle Health Foundation EHR, creating a more integrated environment for managing patient information and using AI to support healthcare decisions.

The first phase will focus on M42’s diabetes programmes. By bringing relevant patient information together, the companies hope to help clinicians monitor changes in patients’ conditions, identify potential risks and coordinate long-term care more effectively.

The project also fits into Abu Dhabi’s broader push to develop industries around artificial intelligence, advanced computing, biotechnology and digital services.

For healthcare providers, the challenge is familiar. Hospitals and clinics collect enormous amounts of information, but it often sits in separate systems that do not communicate easily with one another. Bringing those records together could make it easier for medical teams to access relevant information and make better-informed decisions.

There is, however, an important distinction between the project’s ambitions and its results. The announcement confirms plans to expand healthcare data infrastructure; it does not yet demonstrate measurable improvements in patient outcomes.

WHAT THE M42–ORACLE PARTNERSHIP WILL DO

At the centre of the collaboration is Oracle Health Data Intelligence, a platform designed to bring different types of healthcare information together for clinical care, research and population health management.

M42 intends to integrate the platform with Oracle Health Foundation EHR, an electronic health record system used to manage patient information.

The goal is to give healthcare professionals a more complete view of each patient’s medical history, rather than requiring them to piece together information from separate databases and clinical systems.

According to the companies, the integration is intended to support clinical decision-making, improve coordination between healthcare providers and make relevant information easier to access during treatment.

Three main categories of information will play a role in the planned system.

Clinical data

Clinical data includes diagnoses, laboratory results, prescribed medicines, medical histories and information collected during appointments and treatment.

When these records are connected, doctors may be able to review a patient’s history more efficiently and identify information that might otherwise be missed across separate systems.

Genomic data

Genomic information can help researchers and clinicians understand how genetic differences may influence disease risks or a person's response to certain medicines.

When combined with clinical records, this information may support more personalised treatment decisions, provided there is sufficient scientific evidence to guide its use.

Real-world health data

Real-world health data comes from routine healthcare delivery and patient follow-up. It can help researchers examine how diseases progress, how treatments are used and how patients respond to care outside traditional clinical trials.

Bringing these information sources together could open up new opportunities for research and analysis. The results, however, will depend on the quality of the data, how reliably different systems are connected and whether the resulting insights are useful in everyday clinical practice.

WHY ABU DHABI IS TURNING TO AI-POWERED HEALTHCARE

Abu Dhabi has been building a healthcare technology ecosystem that brings together medical services, genomics, research and artificial intelligence. M42 is one of the major organisations involved in that effort.

Formed in 2023 through the combination of G42 Healthcare and Mubadala Health, M42 operates healthcare facilities and technology platforms across international markets.

The company reported in its September announcement that its network spans more than 480 facilities in 26 countries and includes over 20,000 employees. Its healthcare operations include Cleveland Clinic Abu Dhabi, Imperial College London Diabetes Centre, Danat Al Emarat and other organisations.

That network gives M42 a broad base of clinical expertise and healthcare operations on which to build digital services.

The group is also involved in initiatives covering genomics, biobanking and health information. Bringing those capabilities together with Oracle’s technology could help strengthen its approach to healthcare analytics and AI-supported services.

For Abu Dhabi, the opportunity extends well beyond hospitals. Healthcare AI can create demand for cloud infrastructure, software development, cybersecurity, medical research and specialist data science skills.

Still, the partnership alone does not establish how much additional investment, employment or economic growth it will generate. Those effects will become clearer only as the initiative develops.

DIABETES CARE WILL BE THE FIRST MAJOR TEST

One of the most significant details in the announcement is the decision to begin with diabetes management.

M42 plans to introduce Oracle Health Data Intelligence into its diabetes programmes first, with the aim of supporting earlier intervention, more proactive patient engagement and better coordination of long-term care.

Diabetes is a particularly relevant starting point because managing the condition often involves years of follow-up appointments, laboratory tests, medication reviews and regular monitoring.

Information may be collected by different specialists and healthcare facilities over time. If those records remain disconnected, clinicians can find it harder to build a complete picture of a patient's condition.

A more integrated system could help care teams review medical histories, track relevant changes and coordinate follow-up more effectively.

Identifying potential risks earlier

AI-supported analytics may help clinicians spot patterns in patient records that warrant closer attention.

Changes in laboratory results, medication histories or other clinical measurements could indicate that a patient needs additional monitoring. Such tools must be properly tested before their predictions are used to guide treatment.

Making care more personal

A more complete patient record can help doctors tailor follow-up schedules and treatment discussions to individual needs.

The intention is to give medical professionals better information to work with, not to replace their judgement or responsibility for patient care.

Improving long-term monitoring

Managing a chronic condition is an ongoing process. Patients may need adjustments to their treatment plans as their health changes.

Connected records could make it easier for clinicians to review progress over time and assess whether existing care plans are working as intended.

The initial diabetes rollout will provide an important opportunity to evaluate whether the technology improves coordination and delivers meaningful benefits for patients.

HOW GENOMICS COULD SUPPORT MORE PERSONALISED MEDICINE

The latest initiative builds on earlier work between M42 and Oracle Health involving connected patient records and genomic information.

In 2025, the organisations began collaborating on unified longitudinal patient records, aiming to make relevant information more accessible across the healthcare ecosystem.

As part of that work, information from the Emirati Genome Programme was integrated into electronic health records to help clinicians access pharmacogenomic insights.

Pharmacogenomics examines how genetic differences can influence a person's response to particular medicines. In some situations, this information can help healthcare professionals make better-informed decisions about medication choice or dosage.

The new initiative aims to take this approach further by bringing clinical, genomic and real-world health information into a broader data environment.

Over time, this could support research into disease patterns, treatment responses and opportunities for preventive care.

But genomic information has its limits. Not every disease can be accurately predicted through genetic testing, and not every treatment decision can be personalised using genomic data alone.

Medical decisions must continue to rely on validated scientific evidence, individual patient circumstances and professional clinical judgement. The value of the technology will depend on how effectively it turns complex information into insights that are genuinely useful in practice.

ORACLE’S ROLE IN ABU DHABI’S DIGITAL TRANSFORMATION

Oracle brings its experience in enterprise software, cloud computing and healthcare information systems to the partnership.

Oracle Health Data Intelligence is designed to help healthcare organisations connect information and use analytics to support clinical and operational decisions.

The collaboration also comes as Oracle expands its broader technology presence in the UAE, where demand for cloud services and AI infrastructure is growing.

Oracle is among the technology partners associated with Stargate UAE, an AI infrastructure initiative announced in May 2025 alongside G42, OpenAI, NVIDIA, Cisco and SoftBank.

The project includes plans for a one-gigawatt AI computing cluster in Abu Dhabi, with an initial 200-megawatt phase targeted for 2026.

These developments reflect two sides of Abu Dhabi’s AI strategy: investing in the computing infrastructure needed to run advanced systems and developing applications that can put those capabilities to practical use.

The M42–Oracle healthcare initiative and Stargate UAE are separate projects. Their strategic connection does not establish that M42 patient data will be processed through Stargate infrastructure.

The broader ambition is to create an environment in which cloud computing, AI development and specialised applications can support new industries and help diversify the emirate’s economy.

WHERE AI COULD MAKE A DIFFERENCE IN HEALTHCARE

Artificial intelligence can help healthcare organisations analyse large volumes of information, identify patterns and bring relevant details to the attention of medical professionals.

In clinical settings, these tools may assist with reviewing patient records, highlighting information for further assessment and supporting research into disease progression.

For hospitals and healthcare networks, better-connected information could reduce the time spent searching across systems and help different departments coordinate care.

Researchers may also benefit from access to well-governed datasets that allow them to investigate treatment patterns, potential risk factors and other questions requiring further study.

The M42–Oracle partnership is intended to create a more connected data environment to support these kinds of applications.

But more data does not automatically mean better decisions. AI systems can make mistakes, reflect biases in the information used to develop them or perform differently across patient populations.

Healthcare providers will need to test these systems carefully, monitor their performance and ensure that clinicians remain accountable for medical decisions.

Ultimately, the project's success will depend as much on safe implementation and day-to-day use as on the technology itself.

PATIENT PRIVACY AND DATA SECURITY WILL BE ESSENTIAL

Healthcare records contain some of the most sensitive personal information. Bringing medical histories, genomic information and real-world health data together creates opportunities for better care and research, but it also raises important questions about privacy, access and security.

M42 and Oracle have said the initiative will be supported by data, digital and AI governance principles intended to promote responsible information handling and compliance with applicable requirements.

Several areas will require particular attention as the system develops.

Access controls: Only authorised people and systems should be able to access patient information for legitimate purposes.

Data quality: Incomplete, inaccurate or outdated records can undermine the reliability of clinical insights and AI-generated analysis.

Cybersecurity: Connected healthcare systems need strong safeguards against unauthorised access, data theft and operational disruption.

AI validation: Predictive tools must be evaluated to establish whether they work reliably for the patient groups and clinical situations in which they are used.

Patient rights: Privacy protections, transparency and applicable consent requirements must remain central to the handling of sensitive health information.

The companies have outlined their governance intentions, but the announcement does not independently confirm that every future AI application has completed clinical validation or regulatory review.

Maintaining public trust will be crucial. Patients and healthcare professionals need confidence that sensitive information is handled responsibly and that new technology supports care without introducing unnecessary risks.

WHAT THE PARTNERSHIP COULD MEAN FOR ABU DHABI’S AI ECONOMY

The M42–Oracle initiative reflects Abu Dhabi’s wider effort to develop high-value technology industries alongside established sectors such as energy, finance and manufacturing.

Healthcare is a natural area for that investment. It combines scientific research, specialist skills, digital infrastructure and long-term demand for medical services.

A more connected healthcare data environment could support clinical analytics, precision-medicine research and the development of digital health applications. It could also create opportunities for hospitals, universities, research institutions and technology companies to work together.

For Abu Dhabi, the bigger prize is not simply the introduction of another software platform. It is the potential to develop local expertise, attract investment, build reliable services and create technology that can be used responsibly in healthcare.

M42’s international network may also provide opportunities to apply lessons from the UAE in other markets, subject to local regulations and clinical requirements.

However, the commercial impact remains uncertain. Neither M42 nor Oracle disclosed the financial value of the September agreement, a firm completion date for implementation or a forecast of revenue from the platform.

Those details will be important in assessing the scale of the project and its longer-term contribution to Abu Dhabi’s technology economy.

CONNECTING HEALTHCARE SYSTEMS WILL NOT BE SIMPLE

Bringing healthcare information together involves more than transferring records into a single system.

Hospitals and clinics often use different software, terminology and data formats. The information they hold can also vary in accuracy and completeness, making integration a significant technical and operational challenge.

Genomic data adds another layer of complexity because genetic findings must be interpreted carefully and considered alongside relevant clinical evidence.

Real-world datasets can also contain missing information or inconsistencies that limit their usefulness for research and AI applications.

M42 and Oracle will need to address these issues as the platform is introduced. That will require reliable technical integration, staff training, clear governance arrangements and ongoing assessments of how the system affects clinical workflows.

The aim is to make patient information more useful without adding unnecessary administrative work or creating new risks.

Starting with diabetes programmes could give the companies a practical setting in which to assess the system before considering a broader rollout.

FACT CHECK METER

FACT METER: 98%

STATUS: COLLABORATION CONFIRMED — ADOPTION OF ORACLE HEALTH DATA INTELLIGENCE PLANNED

CONFIRMED: M42 announced plans on 15 September 2026 to adopt Oracle Health Data Intelligence across its healthcare network.

CONFIRMED: The planned platform is intended to connect clinical, genomic and real-world health data and integrate with Oracle Health Foundation EHR.

CONFIRMED: The initial deployment is expected to focus on M42’s diabetes programmes, supporting patient engagement and long-term disease management.

CONFIRMED: The initiative builds on earlier M42–Oracle work involving connected patient records and the integration of Emirati Genome Programme information into electronic health records.

IMPORTANT DISTINCTION: The announcement outlines a planned adoption and its intended benefits. It does not establish that the full platform is already operational or that improved patient outcomes have been clinically demonstrated.

IMPORTANT DISTINCTION: Oracle’s wider AI infrastructure projects in Abu Dhabi, including Stargate UAE, are separate from the M42 healthcare data initiative.

NOT DISCLOSED: The financial value of the agreement, the final implementation date and the project's expected economic returns.

AWX VERDICT: The M42–Oracle collaboration marks a confirmed move towards more connected, AI-enabled healthcare in Abu Dhabi. Its significance lies in the planned integration of clinical, genomic and real-world health information. Whether that translates into better patient care will depend on implementation, clinical validation and measurable results.

WHAT TO WATCH NEXT

1. Diabetes programme rollout: Updates from M42 and Oracle should clarify when the initial deployment begins and how the technology is incorporated into everyday clinical workflows.

2. Patient outcomes: Evidence of better care coordination, more effective monitoring and improvements in chronic disease management will help establish the platform's practical value.

3. Expansion across M42 facilities: Future announcements may reveal whether the system will extend to more hospitals, medical specialties or healthcare programmes.

4. Genomic integration: Further developments in pharmacogenomics and connected patient records could expand the potential applications of personalised medicine.

5. Data governance and security: Details about privacy safeguards, clinical validation and regulatory compliance will be important as the platform handles increasingly complex health information.

6. Commercial and economic impact: New research partnerships, technology deployments and investment commitments could help show whether healthcare AI is generating broader economic benefits for Abu Dhabi.

THE AWX BOTTOM LINE

Abu Dhabi is working towards a healthcare model in which clinical records, genomic information and artificial intelligence can work together to support more personalised and proactive care.

M42’s planned adoption of Oracle Health Data Intelligence is another step in that direction. By connecting different types of healthcare information, the initiative aims to help doctors make better-informed decisions, support medical research and improve the management of chronic conditions.

Diabetes programmes will provide the first important test. The technology will need to demonstrate that it can improve coordination, deliver reliable clinical insights and make a meaningful difference to patient care.

The partnership also reflects Abu Dhabi’s broader ambition to build an AI-driven economy supported by advanced computing, research and specialised technology services.

For now, the announcement establishes the direction rather than the outcome. The real test will be whether the platform can turn connected data into safer, more effective healthcare while protecting patient privacy and maintaining clinical standards.

ATTLAS WIRE | AWX WORLD NEWS

Real Stories. Lasting Impact.